ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.685
      -0.12%
      Bitcoin
      65,240.63
      0.16%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mesoblast Limited (MESO)

      7. Mesoblast Limited (MESO) News

      MESO

      Mesoblast (MESO)

      Mesoblast Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MESO
      DateTimeSourceHeadlineSymbolCompany
      12/17/202010:06PMGlobeNewswire Inc.Mesoblast Webcast – Update on COVID-19 ARDS TrialNASDAQ:MESOMesoblast Limited
      12/17/20206:31PMGlobeNewswire Inc.Mesoblast Update on COVID-19 ARDS TrialNASDAQ:MESOMesoblast Limited
      12/15/20206:36AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      12/14/20205:27PMGlobeNewswire Inc.Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart FailureNASDAQ:MESOMesoblast Limited
      12/14/20204:55PMGlobeNewswire Inc.Mesoblast Corporate UpdateNASDAQ:MESOMesoblast Limited
      12/07/20206:04AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      12/07/20206:00AMGlobeNewswire Inc.Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host DiseaseNASDAQ:MESOMesoblast Limited
      12/02/20206:00AMGlobeNewswire Inc.FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19NASDAQ:MESOMesoblast Limited
      12/01/20206:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      11/23/20206:05AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      11/19/20205:53PMDow Jones NewsMesoblast Up 25% After Hours on Collaboration With NovartisNASDAQ:MESOMesoblast Limited
      11/19/20205:36PMGlobeNewswire Inc.Operational and Financial Results for the Period Ended September 30, 2020NASDAQ:MESOMesoblast Limited
      11/19/20205:11PMGlobeNewswire Inc.Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-LNASDAQ:MESOMesoblast Limited
      11/19/20204:19PMGlobeNewswire Inc.Mesoblast Corporate Update and Financial Results WebcastNASDAQ:MESOMesoblast Limited
      11/13/20206:05AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      11/11/20206:00AMGlobeNewswire Inc.Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 T...NASDAQ:MESOMesoblast Limited
      11/03/20206:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      10/29/20206:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      10/29/20206:00AMGlobeNewswire Inc.Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHDNASDAQ:MESOMesoblast Limited
      10/22/20206:00AMGlobeNewswire Inc.Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn’s Disease and...NASDAQ:MESOMesoblast Limited
      10/21/20205:41PMGlobeNewswire Inc.CytoDyn Appoints Mahboob Rahman, M.D., Ph.D., as Chief Scientific OfficerNASDAQ:MESOMesoblast Limited
      10/15/20206:32AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      10/13/20206:00AMGlobeNewswire Inc.Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Su...NASDAQ:MESOMesoblast Limited
      10/05/20206:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      10/01/20207:25PMGlobeNewswire Inc.Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft...NASDAQ:MESOMesoblast Limited
      09/17/20206:02AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      09/16/20206:01AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      09/15/20206:00AMGlobeNewswire Inc.Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-LNASDAQ:MESOMesoblast Limited
      09/08/20207:32AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      09/04/20206:00AMGlobeNewswire Inc.Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With Acute Respirato...NASDAQ:MESOMesoblast Limited
       Showing the most relevant articles for your search:NASDAQ:MESO